Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

Abstract

We provide evidence that physician's global judgement of walking improvement is a reliable measure for determining response to fampridine in nonwalking parameters, with fatigue showing the greatest score improvement after 2 weeks.